Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients.

Cogn Behav Neurol

Department of Gastroenterology, Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration Hospital, Byzantio, Thessaloniki, Macedonia, Greece.

Published: September 2010

Background: Alzheimer disease (AD) is a progressive, fatal neurodegenerative condition.

Objective: We tested the hypothesis that eradication of Helicobacter pylori infection (Hp-I) could improve survival in a Greek cohort of AD patients, in a 5-year follow-up.

Method: Forty-six patients diagnosed with probable AD were enrolled in the analysis. Study population was classified into 3 groups: patients for whom Hp eradication treatment was successful; those for whom eradication of Hp had failed, they refused, and/or were noncompliant with eradication therapy; and those who were Hp negative at baseline. Cox proportional hazards model was built with all-cause mortality as the dichotomous outcome.

Results: During the 5-year follow-up [47.19±15.11 mo (range 12 to 60)], overall 21 patients died and 25 patients remained alive. Patients who died were older and exhibited lower mean MMSE score compared with the patients still alive. Successful eradication of Hp-I was associated with a significantly lower mortality risk [HR (95% CI)=0.287 (0.114-0.725), P=0.008]. The results were similar in adjusted and unadjusted models, for age and MMSE at baseline.

Conclusion: Hp eradication regimen in AD patients is associated with a higher 5-year survival rate.

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNN.0b013e3181df3034DOI Listing

Publication Analysis

Top Keywords

patients
9
helicobacter pylori
8
alzheimer disease
8
successful eradication
8
patients died
8
eradication
7
five-year survival
4
survival helicobacter
4
pylori eradication
4
eradication alzheimer
4

Similar Publications

Despite the pivotal role of cytotoxic T lymphocytes (CTLs) in anti-tumor immunity, a substantial proportion of CTL-rich hepatocellular carcinoma (HCC) patients experience early relapse or immunotherapy resistance. However, spatial immune variations impacting the heterogeneous clinical outcomes of CTL-rich HCCs remain poorly understood. Here, we compared the single-cell and spatial landscapes of 20 CTL-rich HCCs with distinct prognoses using multiplexed in situ staining and validated the prognostic value of myeloid spatial patterns in a cohort of 386 patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!